AbbVie (NASDAQ:ABBV) is basically a one-trick pony. The trick is an immunosuppressant called Humira, prescribed to fight rheumatoid arthritis and other conditions. It’s the best-selling drug in the world, bringing in $18.4 billion in 2017, but that might not be sufficient to support the future of AbbVie stock. While protected against direct competition in the U.S. until 2023, Humira is already facing biosimilars in Europe, as its protections there disappear.
For now, the good times roll on. AbbVie is due to report earnings Jan. 25, expecting sales of $8.36 billion for a 2018 total of $32.8 billion , 16% ahead of 2017’s $28.2 billion. Net income of $1.92 per share will bring that total to $6.92 per share for the year. But, as they say of both athletes and great beauties, Father Time is undefeated. AbbVie still faces a patent cliff, and growing opposition to rising prices. Nothing lasts forever. What works this year may not work next year. Know that before you buy AbbVie stock.
Source: InvestorPlace
Related Articles:
- 2 Low P/E Value-Stocks, Yielding 4% Or Higher
- 5 Stocks With A Low Debt To Total Capital
- Should You Sell A Dividend Stock After A Dividend Cut?
- All Investing Involves Risk
- 4 Dividend Stocks With Room To Increase Their Payout
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
In this article we discuss the 5 Best Dividend Stocks to Buy According to Billionaire Ken Fisher. 5.) British American Tobacco p.l.c. (NYSE:...
-
Investing for retirement requires a different approach from merely betting on growth or value stocks. The strategy for fixed-income is to bu...
-
On Monday, AT&T (NYSE:T) confirmed that it will spin off its WarnerMedia entertainment unit and merge it with Discovery. While this will...
-
Earlier generations have favored dividend investing because generally higher yields were on offer then. Today, though, some investors have b...
-
One of our favorite areas to find blue-chip dividend stocks is in the utility sector. Companies in this space provide electricity, gas and w...
-
It’s safe to say that one of the biggest concerns that economists and investors have on their minds at this time is inflation. Regardless of...
-
One factor that can make a big difference is competitive advantage and leadership in a given industry. In general, larger companies with glo...
-
Business Development Companies, known as BDCs, offer the retail investor exposure to privately-held firms, which often are funded by venture...
-
If you are considering buying a stock purely for its dividend yield, then you will want to be sure that the dividend can grow in the future....
-
The best dividend stocks don't always come with incredibly generous yields. Excessive dividend yields are often a sign of deeply trouble...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.